We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 1.81% for the day. Elsewhere, the Dow gained 1.56%, while the tech-heavy Nasdaq added 2.06%.
Shares of the company have depreciated by 15% over the course of the past month, underperforming the Medical sector's loss of 12.01% and the S&P 500's loss of 6.14%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.11, reflecting a 120% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $535.94 million, up 92.67% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.63 per share and revenue of $2.34 billion, indicating changes of +133.33% and +58.17%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy).
Looking at its valuation, Hims & Hers Health, Inc. is holding a Forward P/E ratio of 42.27. This expresses a premium compared to the average Forward P/E of 23.17 of its industry.
One should further note that HIMS currently holds a PEG ratio of 1.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Info Systems stocks are, on average, holding a PEG ratio of 2.83 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 44, finds itself in the top 18% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know
Hims & Hers Health, Inc. (HIMS - Free Report) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 1.81% for the day. Elsewhere, the Dow gained 1.56%, while the tech-heavy Nasdaq added 2.06%.
Shares of the company have depreciated by 15% over the course of the past month, underperforming the Medical sector's loss of 12.01% and the S&P 500's loss of 6.14%.
Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be $0.11, reflecting a 120% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $535.94 million, up 92.67% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.63 per share and revenue of $2.34 billion, indicating changes of +133.33% and +58.17%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy).
Looking at its valuation, Hims & Hers Health, Inc. is holding a Forward P/E ratio of 42.27. This expresses a premium compared to the average Forward P/E of 23.17 of its industry.
One should further note that HIMS currently holds a PEG ratio of 1.14. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Medical Info Systems stocks are, on average, holding a PEG ratio of 2.83 based on yesterday's closing prices.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 44, finds itself in the top 18% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.